Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Mechanistic action of the immune-modulatory protein B7-H4 in breast cancer
FY 2025-26
Summary
The immune system plays a key role in eliminating cancer cells. However, cancer cells use various strategies to evade immune attack. One mechanism involves expressing a cell surface protein, called PD-L1, which binds to a molecule on immune cells, called PD-1. This type of interaction, termed an immune checkpoint, acts to suppress an immune response towards the cancer cells. Study of immune checkpoints has led to development of checkpoint inhibitors, therapies which block such interactions and promote anti-tumour immunity, showing clinical success in many cancers. However, not all tumours respond to the same checkpoint therapies, partly due to expression of different checkpoint proteins. Our lab found that a distinct immune-inhibitory protein, B7-H4, is overexpressed by a subset of triple-negative breast cancer tumours associated with low immune response and poor clinical outcome. Its expression was also inversely correlated with that of PD-L1, meaning patients are unlikely to benefit from established PD-L1-targeted therapies. These relationships have been reported in other cancers too, including other breast cancer subtypes, highlighting B7-H4 as a potential alternative checkpoint target. Development of B7-H4-targeted therapies is already underway. However, the biochemical events underlying and regulating B7-H4 functions in normal and cancer contexts remain poorly understood. This project aims to define the molecular mechanisms of B7-H4 cell surface expression, immunomodulation, and cancer-promoting functions using proteomic and structure function approaches. Our findings will elucidate the role of B7-H4 in breast tumours and its utility as a checkpoint target for breast cancer treatment, and carry important implications for the development of B7-H4-targeted therapies.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
573279
Name
Zhou Carol
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mechanistic action of the immune-modulatory protein B7-H4 in breast cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
B7-H4; Breast Cancer; Cellular Signalling; Immune Checkpoint Proteins; Post-Translational Modifications; Protein-Protein Interactions; Proteomics; Structure Function
Abstract
The immune system plays a key role in eliminating cancer cells. However, cancer cells use various strategies to evade immune attack. One mechanism involves expressing a cell surface protein, called PD-L1, which binds to a molecule on immune cells, called PD-1. This type of interaction, termed an immune checkpoint, acts to suppress an immune response towards the cancer cells. Study of immune checkpoints has led to development of checkpoint inhibitors, therapies which block such interactions and promote anti-tumour immunity, showing clinical success in many cancers. However, not all tumours respond to the same checkpoint therapies, partly due to expression of different checkpoint proteins. Our lab found that a distinct immune-inhibitory protein, B7-H4, is overexpressed by a subset of triple-negative breast cancer tumours associated with low immune response and poor clinical outcome. Its expression was also inversely correlated with that of PD-L1, meaning patients are unlikely to benefit from established PD-L1-targeted therapies. These relationships have been reported in other cancers too, including other breast cancer subtypes, highlighting B7-H4 as a potential alternative checkpoint target. Development of B7-H4-targeted therapies is already underway. However, the biochemical events underlying and regulating B7-H4 functions in normal and cancer contexts remain poorly understood. This project aims to define the molecular mechanisms of B7-H4 cell surface expression, immunomodulation, and cancer-promoting functions using proteomic and structure function approaches. Our findings will elucidate the role of B7-H4 in breast tumours and its utility as a checkpoint target for breast cancer treatment, and carry important implications for the development of B7-H4-targeted therapies.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhou, Carol
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~